6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4- dihydroquinolines as HIV integrase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 2, 2011, Pages 760-763

  Nagasawa, Johnny Y ^a   Song, Jenny ^a   Chen, Huanming ^a   Kim, Hong Woo ^a   Blazel, Julie ^a   Ouk, Samedy ^a   Groschel, Bettina ^a   Borges, Virginia ^a   Ong, Voon ^a   Yeh, Li Tain ^a   Girardet, Jean Luc ^a   Vernier, Jean Michel ^a   Raney, Anneke K ^a   Pinkerton, Anthony B ^a,b  

^a Ardea Biosciences Inc   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

HIV; Inhibitors; Integrase; Quinolones

Indexed keywords

4 OXO 1,4 DIHYDROQUINOLINE DERIVATIVE; 6 BENZYLAMINO 4 OXO 1,4 DIHYDRO 1,8 NAPHTHYRIDINE DERIVATIVE; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; HAPLORHINI; HUMAN; LIVER MICROSOME METABOLISM; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOGS; HAPLORHINI; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROSOMES, LIVER; NAPHTHYRIDINES; QUINOLINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78651238387     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.108     Document Type: Article

References (11)

1. R. Craigie J. Biol. Chem. 276 2001 23213
2. A. Engelman, K. Mizuuchi, and R. Craigie Cell 67 1991 1211
3. Y. Pommier, A.A. Johnson, and C. Marchand Nat. Rev. Drug Disc. 4 2005 236
4. E. Serrao, S. Odde, K. Ramkumar, and N. Neamati Retrovirology 6 2009 25
5. S.G. Deeks, S. Kar, S.I. Gubernick, and P. Kirkpatrick Nat. Rev. Drug Disc. 7 2008 117
6. V. Summa, A. Petrocchi, F. Bonelli, B. Crescenzi, M. Donghi, M. Ferrara, F. Fiore, C. Gardelli, O.G. Paz, D.J. Hazuda, P. Jones, O. Kinzel, R. Laufer, E. Monteagudo, E. Muraglia, E. Nizi, F. Orvieto, P. Pace, G. Pescatore, R. Scarpelli, K. Stillmock, M.V. Witmer, and M. Rowley J. Med. Chem. 51 2008 5843
7. M. Sato, H. Kawakami, T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita, Y. Ito, Y. Matsuzaki, K. Yamataka, S. Ikeda, and H. Shinkai J. Med. Chem. 52 2009 4869
8. M. Sato, T. Motomura, H. Aramaki, T. Matsuda, M. Yamashita, Y. Ito, H. Kawakami, Y. Matsuzaki, W. Watanabe, K. Yamataka, S. Ikeda, E. Kodama, M. Matsuoka, and H. Shinkai J. Med. Chem. 49 2006 1506
9. For complete schemes and experimental procedures, including for compounds 13-15, see: Chen, H.; Song, J.; Vernier, J.-M.; Pinkerton, A. B.; Nagasawa, J. Y. PCT WO 2009/089263.
10. 50 values were determined by non-linear regression analysis using GraphPad Prism4 software. The SAR was guided by the potency of the compounds in the presence of 40% human serum as an estimation of the antiviral activity of the compound while circulating in the presence of plasma proteins in vivo.
11. Z. Zhang, W. Xu, Y.-H. Koh, J.H. Shim, J.-L. Girardet, L.-T. Yeh, R.K. Hamatake, and Z. Hong Antimicrob. Agents Chemother. 51 2007 429